SCM
RCUS icon

Suvretta Capital Management’s Arcus Biosciences RCUS Stock Holding History

Suvretta Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147M Sell
4,776,423
-254,570
-5% -$6.29M 2.69% 10
2026
Q1 		$109M Sell
5,030,993
-157,865
-3% -$3.41M 2.78% 10
2025
Q4 		$124M Buy
5,188,858
+1,500,000
+41% +$30.6M 2.53% 7
2025
Q3 		$50.2M Hold
3,688,858
– – 1.28% 30
2025
Q2 		$30M Buy
3,688,858
+1,127,954
+44% +$9.63M 0.91% 35
2025
Q1 		$20.1M Buy
2,560,904
+1,984,748
+344% +$23M 0.75% 37
2024
Q4 		$8.58M Sell
576,156
-87,447
-13% -$1.43M 0.29% 57
2024
Q3 		$10.1M Sell
663,603
-293,701
-31% -$4.63M 0.32% 52
2024
Q2 		$14.6M Hold
957,304
– – 0.54% 45
2024
Q1 		$18.1M Hold
957,304
– – 0.67% 42
2023
Q4 		$18.3M Buy
957,304
+360,205
+60% +$5.76M 0.83% 38
2023
Q3 		$10.7M Buy
+597,099
New +$12M 0.58% 44

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Suvretta Capital Management's RCUS Position: Q2 2026 in Review

Suvretta Capital Management reduced its Arcus Biosciences (RCUS) stake by 5.1% in Q2 2026, selling an estimated $6.29M and leaving 4,776,423 shares worth $147M. The position accounts for 2.69% of the portfolio, ranked #10.

Suvretta Capital Management first reported a position in RCUS in Q3 2023 and has held it in 12 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Suvretta Capital Management held 4,776,423 shares of Arcus Biosciences worth $147M as of Q2 2026.
  • Suvretta Capital Management sold 254,570 Arcus Biosciences shares in Q2 2026, an estimated $6.29M.
  • Arcus Biosciences made up 2.69% of Suvretta Capital Management's portfolio in Q2 2026, its #10 holding.
  • Suvretta Capital Management first reported a position in Arcus Biosciences in Q3 2023 and has held it in 12 quarters since.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.